FR04C0032I2 - Nouveaux derives de quinuclidine et composition pharmaceutique les contenant - Google Patents

Nouveaux derives de quinuclidine et composition pharmaceutique les contenant

Info

Publication number
FR04C0032I2
FR04C0032I2 FR04C0032C FR04C0032C FR04C0032I2 FR 04C0032 I2 FR04C0032 I2 FR 04C0032I2 FR 04C0032 C FR04C0032 C FR 04C0032C FR 04C0032 C FR04C0032 C FR 04C0032C FR 04C0032 I2 FR04C0032 I2 FR 04C0032I2
Authority
FR
France
Prior art keywords
pharmaceutical compositions
compositions containing
quinuclidine derivatives
new quinuclidine
new
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
FR04C0032C
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Astellas Pharma Inc
Original Assignee
Astellas Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=18194699&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FR04C0032(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astellas Pharma Inc filed Critical Astellas Pharma Inc
Publication of FR04C0032I1 publication Critical patent/FR04C0032I1/fr
Application granted granted Critical
Publication of FR04C0032I2 publication Critical patent/FR04C0032I2/fr
Active legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C07D221/04—Ortho- or peri-condensed ring systems
    • C07D221/06—Ring systems of three rings
    • C07D221/10—Aza-phenanthrenes
    • C07D221/12—Phenanthridines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
    • C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
    • C—CHEMISTRY; METALLURGY
    • C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
    • C09K—MATERIALS FOR MISCELLANEOUS APPLICATIONS, NOT PROVIDED FOR ELSEWHERE
    • C09K19/00—Liquid crystal materials
    • C09K19/04—Liquid crystal materials characterised by the chemical structure of the liquid crystal components, e.g. by a specific unit
    • C09K19/06—Non-steroidal liquid crystal compounds
    • C09K19/34—Non-steroidal liquid crystal compounds containing at least one heterocyclic ring
    • C09K19/3441—Non-steroidal liquid crystal compounds containing at least one heterocyclic ring having nitrogen as hetero atom
    • C09K19/3444—Non-steroidal liquid crystal compounds containing at least one heterocyclic ring having nitrogen as hetero atom the heterocyclic ring being a six-membered aromatic ring containing one nitrogen atom, e.g. pyridine

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Materials Engineering (AREA)
  • Communicable Diseases (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Tea And Coffee (AREA)
  • External Artificial Organs (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
FR04C0032C 1994-12-28 2004-12-30 Nouveaux derives de quinuclidine et composition pharmaceutique les contenant Active FR04C0032I2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP32704594 1994-12-28
PCT/JP1995/002713 WO1996020194A1 (fr) 1994-12-28 1995-12-27 Nouveaux derives de quinuclidine et composition pharmaceutique les contenant

Publications (2)

Publication Number Publication Date
FR04C0032I1 FR04C0032I1 (fr) 2005-02-11
FR04C0032I2 true FR04C0032I2 (fr) 2005-10-21

Family

ID=18194699

Family Applications (1)

Application Number Title Priority Date Filing Date
FR04C0032C Active FR04C0032I2 (fr) 1994-12-28 2004-12-30 Nouveaux derives de quinuclidine et composition pharmaceutique les contenant

Country Status (24)

Country Link
US (2) US6017927A (fr)
EP (1) EP0801067B1 (fr)
JP (1) JP3014457B2 (fr)
KR (1) KR100386487B1 (fr)
CN (1) CN1045601C (fr)
AT (1) ATE233761T1 (fr)
AU (1) AU695616B2 (fr)
CA (1) CA2208839C (fr)
DE (2) DE122004000048I2 (fr)
DK (1) DK0801067T3 (fr)
ES (1) ES2193208T3 (fr)
FI (1) FI115631B (fr)
FR (1) FR04C0032I2 (fr)
HU (1) HU223778B1 (fr)
LU (1) LU91133I9 (fr)
MX (1) MX9704880A (fr)
NL (1) NL300141I1 (fr)
NO (4) NO2005012I1 (fr)
NZ (1) NZ298144A (fr)
PL (1) PL182344B1 (fr)
PT (1) PT801067E (fr)
RU (1) RU2143432C1 (fr)
TW (1) TW305842B (fr)
WO (1) WO1996020194A1 (fr)

Families Citing this family (104)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100137358A1 (en) * 1996-11-05 2010-06-03 Dr. Reddy's Laboratories Ltd. Solifenacin compositions
FR2772378B1 (fr) * 1997-12-12 2000-02-04 Synthelabo Derives d'imidazole, leur preparation et leur application en therapeutique
ES2165768B1 (es) 1999-07-14 2003-04-01 Almirall Prodesfarma Sa Nuevos derivados de quinuclidina y composiciones farmaceuticas que los contienen.
US7214687B2 (en) 1999-07-14 2007-05-08 Almirall Ag Quinuclidine derivatives and medicinal compositions containing the same
JP2001316670A (ja) * 2000-05-02 2001-11-16 Dainippon Ink & Chem Inc 液晶組成物
AU2001266100B9 (en) 2000-06-27 2005-10-06 Laboratorios S.A.L.V.A.T., S.A. Carbamates derived from arylalkylamines
EP1345937B1 (fr) * 2000-12-22 2005-09-28 Almirall Prodesfarma AG Derives de carbamate quinuclidine et leur utilisation comme antagonistes m3
SI1353919T1 (sl) * 2000-12-28 2006-12-31 Almirall Prodesfarma Ag Novi derivati kinuklidina in medicinske zmesi, kijih vsebujejo.
US7335668B2 (en) * 2001-07-10 2008-02-26 Astellas Pharma Inc. Pharmaceutical composition for therapy of interstitial cystitis
CA2470956C (fr) 2001-12-20 2011-08-02 Laboratorios S.A.L.V.A.T., S.A. Derives de 1-alkyl-1- azoniabicyclo[2.2.2]octane carbamate
CN100355419C (zh) * 2002-06-07 2007-12-19 安斯泰来制药有限公司 治疗膀胱过度活动的药物
ES2203327B1 (es) * 2002-06-21 2005-06-16 Almirall Prodesfarma, S.A. Nuevos carbamatos de quinuclidina y composiciones farmaceuticas que los contienen.
ES2204295B1 (es) * 2002-07-02 2005-08-01 Almirall Prodesfarma, S.A. Nuevos derivados de quinuclidina-amida.
EA200500173A1 (ru) 2002-07-08 2005-08-25 Рэнбакси Лабораториз Лимитед Производные 3,6-дизамещенного азабицикло[3.1.0]гексана в качестве антагонистов мускариновых рецепторов
EP1546098B1 (fr) 2002-07-31 2008-05-28 Ranbaxy Laboratories Limited Derivés 3,6-disubstitués d'azabicyclo[3.1.0]hexane utilisés comme antagonistes des récepteurs muscariniques
HK1079708A1 (zh) 2002-08-09 2006-04-13 Ranbaxy Laboratories, Ltd. 可用作毒蕈碱性受体拮抗剂的3，6-二取代氮杂二环[3．1．10]己烷衍生物
EP1534675B1 (fr) 2002-08-23 2009-02-25 Ranbaxy Laboratories, Ltd. Derives d'azabicyclo(3.1.0)hexanes 3,6-disubstitues contenant fluoro et sulfonylamino, utilises comme antagonistes des recepteurs de muscarine
MXPA05003398A (es) * 2002-10-29 2005-06-22 Pharmacia & Upjohn Co Llc Compuestos de amonio cuaternario.
AU2002353286A1 (en) 2002-12-10 2004-06-30 Ranbaxy Laboratories Limited 3,6-disubstituted azabicyclo (3.1.0) hexane derivatives as muscarinic receptor antagonists
CA2510292A1 (fr) * 2002-12-20 2004-07-15 Dynogen Pharmaceuticals, Inc. Methodes de traitement de troubles de la vessie non douloureux au moyen de modulateurs du canal calcique de la sous unite ?<sb>2</sb>?
AU2002347553A1 (en) * 2002-12-23 2004-07-14 Ranbaxy Laboratories Limited Flavaxate derivatives as muscarinic receptor antagonists
WO2004056767A1 (fr) 2002-12-23 2004-07-08 Ranbaxy Laboratories Limited Derives de 1-substitues-3-pyrrolidines comme antagonistes de recepteurs muscariniques
US7488748B2 (en) 2003-01-28 2009-02-10 Ranbaxy Laboratories Limited 3,6-Disubstituted azabicyclo hexane derivatives as muscarinic receptor antagonists
KR100742001B1 (ko) * 2003-03-21 2007-07-23 다이노젠 파마세우티컬스, 인코포레이티드 평활근 모듈레이터 및 알파2 델타 서브유닛 칼슘 채널모듈레이터를 이용한 하부 요로 질환의 치료 방법
EP1618091A1 (fr) 2003-04-09 2006-01-25 Ranbaxy Laboratories, Ltd. Derives d'azabicyclo hexane substitues en tant qu'antagonistes de recepteurs muscariniques
EP1615634B1 (fr) 2003-04-10 2007-05-16 Ranbaxy Laboratories, Ltd. Derives d'azabicyclo hexane en tant qu'antagonistes des recepteurs muscariniques
WO2004089899A1 (fr) 2003-04-10 2004-10-21 Ranbaxy Laboratories Limited Derives d’azabicyclo hexanes 3,6-disubstitues en tant qu’antagonistes des recepteurs muscariniques
WO2004089900A1 (fr) 2003-04-11 2004-10-21 Ranbaxy Laboratories Limited Derives azabicyclo utiles comme antagonistes du recepteur muscarinique
WO2004091597A2 (fr) * 2003-04-15 2004-10-28 Pharmacia & Upjohn Company Llc Procede pour traiter le syndrome du colon irritable
US20050175689A1 (en) * 2003-10-27 2005-08-11 Yamanouchi Pharmaceutical Co., Ltd. Coated fine particles containing drug for intrabuccally fast disintegrating tablet
JPWO2005075474A1 (ja) * 2004-02-09 2007-10-11 アステラス製薬株式会社 コハク酸ソリフェナシン含有組成物
WO2005077364A1 (fr) * 2004-02-18 2005-08-25 Yamanouchi Pharmaceutical Co., Ltd. Préparation transdermique de solifénacine et procédé d'amélioration de la perméabilité transdermique de celle-ci
ES2239546B1 (es) * 2004-03-15 2006-12-01 Almirall Prodesfarma, S.A. Nuevos esteres de quinuclidina cuaternizados.
JPWO2005087231A1 (ja) * 2004-03-16 2008-01-24 アステラス製薬株式会社 ソリフェナシン含有組成物
CA2560080A1 (fr) * 2004-03-16 2005-09-22 Astellas Pharma Inc. Composition contenant de la solifenacine
ZA200608614B (en) * 2004-03-25 2008-06-25 Astellas Pharma Inc Composition for solid pharmaceutical preparation of solifenacin or salt thereof
US8039482B2 (en) * 2004-03-25 2011-10-18 Astellas Pharma Inc. Composition of solifenacin or salt thereof for use in solid formulation
SE0400970D0 (sv) * 2004-04-14 2004-04-14 Astrazeneca Ab Nicotinic acetylcholine receptor ligands
WO2006035280A1 (fr) * 2004-09-27 2006-04-06 Ranbaxy Laboratories Limited Antagonistes des recepteurs muscariniques
WO2006035303A1 (fr) * 2004-09-29 2006-04-06 Ranbaxy Laboratories Limited Antagonistes de recepteurs muscariniques
JP2008525464A (ja) * 2004-12-22 2008-07-17 メモリー・ファーマシューティカルズ・コーポレイション α−７ニコチン性受容体リガンド並びにその製造及び使用
BG1677U1 (bg) * 2004-12-27 2013-04-30 Astellas Pharma Inc.Astellas Pharma Inc. Фармацевтичен състав със стабилни частици на солифенацин или негова сол
WO2006070735A1 (fr) 2004-12-27 2006-07-06 Astellas Pharma Inc. Préparation pharmaceutique granulaire stable de solifénacine ou de son sel
EP1852117A4 (fr) * 2005-02-25 2010-10-27 Astellas Pharma Inc Agent pharmaceutique comprenant de la solifenacine
JP3701964B1 (ja) * 2005-03-08 2005-10-05 アステラス製薬株式会社 キヌクリジン誘導体の新規な塩
EP1904495A2 (fr) * 2005-07-11 2008-04-02 Ranbaxy Laboratories Limited Antagonistes des recepteurs muscariniques
US7815939B2 (en) 2005-07-20 2010-10-19 Astellas Pharma Inc. Coated fine particles containing drug for intrabuccally fast disintegrating dosage forms
WO2007045979A1 (fr) 2005-10-19 2007-04-26 Ranbaxy Laboratories Limited Compositions pharmaceutiques d'antagonistes du recepteur muscarinique
JP2008535931A (ja) * 2005-12-21 2008-09-04 テバ ファーマシューティカル インダストリーズ リミティド ソリフェナシンの調製方法
CZ300699B6 (cs) * 2006-06-21 2009-07-22 Zentiva, A. S. Zpusob prípravy solifenacinu
EP2046751A4 (fr) * 2006-07-19 2010-12-29 Reddys Lab Ltd Dr Procédé de fabrication de solifénacine et de ses sels
ES2298049B1 (es) 2006-07-21 2009-10-20 Laboratorios Almirall S.A. Procedimiento para fabricar bromuro de 3(r)-(2-hidroxi-2,2-ditien-2-ilacetoxi)-1-(3-fenoxipropil)-1-azoniabiciclo (2.2.2) octano.
EP2043639A2 (fr) * 2006-07-24 2009-04-08 Teva Pharmaceutical Industries Ltd. Procédés de préparation de forme polymorphes de succinate de solifénacine
WO2008019055A2 (fr) * 2006-08-03 2008-02-14 Teva Pharmaceutical Industries Ltd. Procédé de dédoublement optique de 1-phényl-1,2,3,4-tétrahydroisoquinoléine
TW200825084A (en) * 2006-11-14 2008-06-16 Astrazeneca Ab New compounds 521
WO2008062282A2 (fr) * 2006-11-22 2008-05-29 Medichem S.A. Procédé perfectionné pour la synthèse de solifénacine
CZ300692B6 (cs) * 2006-12-22 2009-07-15 Zentiva, A. S. Zpusob prípravy solifenacinu
BRPI0809652A2 (pt) * 2007-03-30 2014-10-07 Medichen S A Processo melhorado para a síntese de solifenacina
EP2146693A2 (fr) * 2007-04-11 2010-01-27 Dr. Reddy's Laboratories Ltd. Compositions à base de solifénacine
WO2009011844A1 (fr) * 2007-07-13 2009-01-22 Teva Pharmaceutical Industries Ltd. Procédés pour la préparation de solifénacine
CA2697137A1 (fr) * 2007-07-20 2009-01-29 Astellas Pharma Inc. Composition pharmaceutique pour une amelioration du symptome des voies urinaires inferieures associe a une prostatomegalie
EP2018850A1 (fr) * 2007-07-24 2009-01-28 Ratiopharm GmbH Composition pharmaceutique comportant de la solifénacine ou sel acceptable pharmaceutiquement
SI2216021T1 (sl) * 2007-11-02 2013-01-31 Astellas Pharma Inc. Farmacevtski sestavek za zdravljenje prekomerno aktivnega sečnega mehurja
JP2011505416A (ja) * 2007-12-04 2011-02-24 カディラ ヘルスケア リミティド 化学的及びキラル的に純粋なソリフェナシン塩基及びその塩を調製する方法
US8476297B2 (en) 2007-12-04 2013-07-02 Amgen Inc. TRP-M8 receptor ligands and their use in treatments
ITMI20080195A1 (it) 2008-02-08 2009-08-09 Dipharma Francis Srl Procedimento per la preparazione di solifenacin
EP2100599A1 (fr) 2008-03-13 2009-09-16 Laboratorios Almirall, S.A. Composition à inhaler comprenant aclidinium pour le traitement de l'asthme et de maladies respiratoires obstructives chroniques
EP2100598A1 (fr) 2008-03-13 2009-09-16 Laboratorios Almirall, S.A. Composition à inhaler comprenant aclidinium pour le traitement de l'asthme et de maladies respiratoires obstructives chroniques
EP4088717A1 (fr) 2008-03-27 2022-11-16 Chase Pharmaceuticals Corporation Association d'un nspacha (agent anticholinergique peripherique) comme la solifenacine et d'un achei (inhibiteur de l'acetyl choline esterase) comme le donepezil pour traiter la demence
PL385264A1 (pl) 2008-05-23 2009-12-07 Zakłady Farmaceutyczne POLPHARMA Spółka Akcyjna Sposób wytwarzania enancjomerycznie czystej (S)-1-fenylo-1, 2, 3, 4-tetrahydroizochinoliny
PL385265A1 (pl) * 2008-05-23 2009-12-07 Zakłady Farmaceutyczne POLPHARMA Spółka Akcyjna Sposób wytwarzania solifenacyny i/lub jej soli o wysokiej czystości farmaceutycznej
EP3067353B1 (fr) 2008-07-29 2017-11-22 KRKA, D.D., Novo Mesto Procédé de préparation de sels de solifénacine et leur inclusion dans des formes posologiques pharmaceutiques
EP2181707A1 (fr) 2008-11-04 2010-05-05 Astellas Ireland Co., Ltd. Utilisation combinée d'un antagoniste de récepteur alpha-adrénergique et d'un agent anti-muscarinique
AU2010211725C1 (en) 2009-02-04 2014-10-16 Astellas Pharma Inc. Pharmaceutical composition for oral administration
WO2010103529A1 (fr) * 2009-03-09 2010-09-16 Megafine Pharma(P) Ltd. Nouveau procédé de préparation de la solifénacine et nouvel intermédiaire dans sa préparation
JP4816828B2 (ja) 2009-03-30 2011-11-16 アステラス製薬株式会社 ソリフェナシン非晶質体を含有した固形医薬組成物
WO2011048607A1 (fr) * 2009-09-25 2011-04-28 Cadila Healthcare Limited Procédés de préparation de solifénacine ou d'un de ses sels
PL234208B1 (pl) 2010-01-18 2020-01-31 Zakl Farmaceutyczne Polpharma Spolka Akcyjna Sposób wytwarzania bursztynianu solifenacyny
ES2604705T3 (es) 2010-03-31 2017-03-08 Ono Pharmaceutical Co., Ltd. Agente preventivo y/o remedio para el síndrome mano-pie
CA2796877A1 (fr) 2010-04-30 2011-11-03 Merck Sharp & Dohme Corp. Nouveaux agonistes du recepteur beta 3 adrenergique
EA023294B1 (ru) 2010-05-19 2016-05-31 Астеллас Фарма Инк. Фармацевтическая композиция, содержащая солифенацин
US8772491B2 (en) 2010-06-28 2014-07-08 Aurobindo Pharma Ltd Process for the preparation of solifenacin succinate
JP5826262B2 (ja) 2010-07-05 2015-12-02 クリスタル ファーマ，エセ．ア．ウ． ソリフェナシン塩
CA2817336A1 (fr) 2010-11-11 2012-05-18 Hexal Ag Succinate de solifenacine cristallin
EP2510928A1 (fr) 2011-04-15 2012-10-17 Almirall, S.A. Aclidinium pour l'amélioration du sommeil des patients avec des maldadies respiratoires
EP2706997B1 (fr) 2011-05-10 2019-03-27 TheraVida, Inc. Combinaisons de solifénacine et pilocarpine pour le traitement d'une vessie hyperactive
US20140228575A1 (en) 2011-06-22 2014-08-14 Isochem Process for the Preparation of Solifenacin and Salts Thereof
KR101365849B1 (ko) 2012-03-28 2014-02-24 경동제약 주식회사 솔리페나신 또는 그의 염의 제조방법 및 이에 사용되는 신규 중간체
JP2015521635A (ja) * 2012-07-02 2015-07-30 ファーマシェン エス．エー． ソリフェナシン又はその塩の調製方法
TW201424772A (zh) 2012-08-31 2014-07-01 Astellas Pharma Inc 經口投與用醫藥組成物
AU2013312749B2 (en) 2012-09-05 2018-01-18 Chase Pharmaceuticals Corporation Anticholinergic neuroprotective composition and methods
CN103787969B (zh) 2012-10-30 2016-07-06 上海京新生物医药有限公司 一种(1s)-1-苯基-3,4-二氢-2（1h）-异喹啉甲酸酯的制备方法
CN104854105B (zh) * 2012-12-06 2017-05-17 奇斯药制品公司 具有毒蕈碱受体拮抗剂和β2肾上腺素能受体激动剂活性的化合物
EP2778167A1 (fr) 2013-03-11 2014-09-17 Abdi Ibrahim Ilac Sanayi Ve Ticaret Anonim Sirketi Composition pharmaceutique comprenant solifenacin ou l'un de ses sels pharmaceutiquement acceptable
RU2641285C2 (ru) * 2013-07-13 2018-01-17 Бэйцзин Фсвэлкам Текнолоджи Девелопмент Ко., Лтд Соединения хинина, способ их получения и их медицинское применение
US20170065589A1 (en) 2014-05-06 2017-03-09 Anthony G. Visco Methods of treating or preventing preterm labor
CN104592221A (zh) * 2015-01-26 2015-05-06 中山奕安泰医药科技有限公司 一种合成索非那新的工艺
KR20160146428A (ko) 2015-06-12 2016-12-21 한미정밀화학주식회사 솔리페나신 또는 그의 약학적으로 허용되는 염과 락토즈를 포함하는 안정한 무정형 솔리페나신 약학 조성물 및 그의 제조방법
KR102148414B1 (ko) 2017-05-15 2020-08-26 주식회사 서울제약 솔리페나신을 유효성분으로 하는 구강붕해필름
TW201927783A (zh) * 2017-12-12 2019-07-16 美商阿爾庫達醫療公司 顆粒體蛋白前體調節劑及其使用方法
MY202833A (en) 2018-05-08 2024-05-24 Nippon Shinyaku Co Ltd Azabenzimidazole compounds and pharmaceutical
JP2022545314A (ja) * 2019-06-12 2022-10-27 アルクダ セラピューティクス プログラニュリンモジュレーターおよびその使用方法
CA3161582A1 (fr) 2019-11-13 2021-05-20 Nippon Shinyaku Co., Ltd. Compose azabenzimidazole et medicament
CN113200979A (zh) * 2021-04-13 2021-08-03 上海予君生物科技发展有限公司 一种琥珀酸索非那新的合成工艺

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3687980T2 (de) * 1986-01-07 1993-06-17 Beecham Group Plc Indolderivate mit einer azabicyclischen seitenkette, verfahren zu ihrer herstellung, zwischenprodukte und pharmazeutische zusammensetzungen.
IT1231238B (it) * 1987-09-21 1991-11-26 Angeli Inst Spa Derivati ammidinici
IT1228293B (it) * 1989-02-06 1991-06-07 Angeli Inst Spa Benzoderivati di composti eterociclici contenenti azoto.
IT1230881B (it) * 1989-06-20 1991-11-08 Angeli Inst Spa Derivati del r(-) 3-chinuclidinolo
GB9023023D0 (en) * 1990-10-23 1990-12-05 Barlow Richard B Pharmaceutical compositions
GB9202443D0 (en) * 1992-02-05 1992-03-18 Fujisawa Pharmaceutical Co A novel substituted-acetamide compound and a process for the preparation thereof
JPH076635A (ja) * 1993-06-18 1995-01-10 Sony Corp 信号伝送ケーブル
AU7545894A (en) * 1993-09-02 1995-03-22 Yamanouchi Pharmaceutical Co., Ltd. Carbamate derivative and medicine containing the same
JPH07258250A (ja) * 1994-03-25 1995-10-09 Yamanouchi Pharmaceut Co Ltd エステル誘導体
DE60308296T2 (de) * 2002-11-27 2007-09-06 Selmac S.R.L., Vigevano Vorrichtung zum Positionieren und Spannen geformter Teile und damit ausgerüstete Maschine

Also Published As

Publication number Publication date
PT801067E (pt) 2003-07-31
FI972775A0 (fi) 1997-06-27
AU695616B2 (en) 1998-08-20
US6017927A (en) 2000-01-25
NL300141I2 (nl) 2004-04-01
NO973027D0 (no) 1997-06-27
NO2005012I1 (no) 2005-06-06
PL321019A1 (en) 1997-11-24
HUT77006A (hu) 1998-03-02
EP0801067A1 (fr) 1997-10-15
HU223778B1 (hu) 2005-01-28
WO1996020194A1 (fr) 1996-07-04
FR04C0032I1 (fr) 2005-02-11
EP0801067B1 (fr) 2003-03-05
TW305842B (fr) 1997-05-21
DE69529844D1 (de) 2003-04-10
LU91133I2 (fr) 2005-03-29
CA2208839A1 (fr) 1996-07-04
NO318026B1 (no) 2005-01-24
CA2208839C (fr) 2006-01-31
RU2143432C1 (ru) 1999-12-27
DE69529844T2 (de) 2004-03-04
AU4355396A (en) 1996-07-19
NO2017055I1 (no) 2017-11-06
ES2193208T3 (es) 2003-11-01
NO2017055I2 (no) 2017-11-06
KR100386487B1 (ko) 2003-09-26
NO973027L (no) 1997-08-28
JPH09508401A (ja) 1997-08-26
NL300141I1 (nl) 2004-04-01
CN1171109A (zh) 1998-01-21
FI115631B (fi) 2005-06-15
DE122004000048I2 (de) 2006-02-02
DK0801067T3 (da) 2003-06-30
LU91133I9 (en) 2018-08-01
NZ298144A (en) 1998-04-27
EP0801067A4 (fr) 1998-03-11
US6174896B1 (en) 2001-01-16
CN1045601C (zh) 1999-10-13
KR987000303A (ko) 1998-03-30
FI972775A7 (fi) 1997-08-22
DE122004000048I1 (de) 2005-04-21
ATE233761T1 (de) 2003-03-15
MX9704880A (es) 1997-10-31
NO2005016I1 (no) 2005-08-29
PL182344B1 (pl) 2001-12-31
JP3014457B2 (ja) 2000-02-28
NO2005016I2 (no) 2008-02-11

Similar Documents

Publication Publication Date Title
DZ2361A1 (fr) Dérivés de 6-phénylpyridyl-2-amine et compositionspharmaceutiques les contenant
DZ2086A1 (fr) Benzylaminopipéridines substituées et compositionspharmaceutiques les contenant.
DZ1916A1 (fr) Composés nouveaux et compostions pharmaceutiques les contenant.
DZ2461A1 (fr) Dérivés d&#39;arylkylamines nouveaux et composition pharmaceutiques les contenant.
MA26537A1 (fr) Derives de 2-aminopyridine nouveaux et compositions pharmaceutiques les contenant.
FR2602974B1 (fr) Composition pharmaceutique contenant de la nicotine ou ses derives
EP0729354A4 (fr) Derives de farnesyle et compositions pharmaceutiques contenant ces derives
MA23895A1 (fr) Amides therapeutiques et compositions les contenant
FR2567885B1 (fr) Derives 3-aminopropoxyaryliques, leur preparation, leur application comme medicaments et compositions pharmaceutiques les contenant
MA23753A1 (fr) Procede de preparation de derives de piperidine nouveaux et de compositions pharmaceutiques contenant ces composes
FR2586562B1 (fr) Composition pharmaceutique contenant de l&#39;a-methylhistamine
FR2764800B1 (fr) Composition pharmaceutique solide contenant des derives de benzofuranne
LU80795A1 (fr) Nouveaux derives de thienohydantoine et composition pharmaceutique les contenant
EP1076547A4 (fr) Derives de l&#39;arabinogalactane et compositions les contenant
BE887970A (fr) Nouveaux derives d&#39;ocytocine et compositions pharmaceutiques contenant ces derives
FR2751540B1 (fr) Composition pharmaceutique antithrombotique
FR2626002B1 (fr) Nucleosides dideoxydidehydrocarbocycliques et composition pharmaceutique les contenant
FR2740134B1 (fr) Derives d&#39;amines cycliques d&#39;aryl-piperazines, leur preparation et les compositions pharmaceutiques les contenant
EE9800069A (et) Bensotiasolooni derivaadid, protsessid ja kasutatud vaheühendid nende saamiseks ning neid sisaldavad ravimkoostised
FR2626175B1 (fr) Composes nouveaux de 1,2-ethylenediamine et composition pharmaceutique les contenant
FR2752422B1 (fr) Composition pharmaceutique contenant des acides 4-oxo-butanoiques
FI971427A7 (fi) Peptidit ja niitä sisältävät farmaseuttiset koostumukset
FR2772761B1 (fr) Nouveaux derives de n-phenylamide et n-pyridylamide, leur procede de preparation et compositions pharmaceutiques les contenant
FR2776659B1 (fr) Nouveaux composes heteroethynylenes et compositions pharmaceutiques et cosmetiques les contenant
FR2641276B1 (fr) Derives du benzene, leur preparation et les compositions pharmaceutiques en contenant